Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

Judd W. Moul, MD
Published: Friday, Oct 30, 2015



Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.



Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x